Pipeline

Team

Board of Directors
Scientific Advisory Board
Leadership and Staff

Investors

Elixiron Immunotherapeutics was founded in April 2017 with initial seed funding from a private angel investor group followed by Series A funding from a VC consortium led by Taiwania Capital, with $16.5M total capital raised as of January 2020. Investment and partnership interest to bring our promising therapeutics candidates to patients or to discuss new opportunities is welcome - Contact Us


Taiwanaia2.png

CDIB_3.png

Axil Capital_3.png

TaiAn_2.png


    

   


News

Contact


Elixiron Immunotherapeutics

3 Park Street, 17th Floor, Taipei City 11503, Taiwan


Elixiron Immunotherapeutics (China) Ltd

No.1 South Building, 5th Floor, JinChuang Mansion, 4560 Jinke Rd, Shanghai 201210, China


Investor inquiries: investors@elixiron.com

Media inquiries: media@elixiron.com

Careers and general inquiries: info@elixiron.com